Applied DNA Q2 fiscal 2025 revenue up 6% to $983k; net loss narrows to $3.3M

BNB PLUS CORP.

2025-Q2 EPS reported -$33.82 vs consensus -$38.25 ▲ beat (+11.6%)

Total revenues $983k (+6% YoY); LineaRx up 44% while MDx testing fell 33%.
Net loss $3.3M vs $4.5M prior year; operating loss $3.5M; adjusted EBITDA -$3.3M.
Cash $6.8M at quarter end; expects quarterly cash burn to decline starting June 30, 2025.
GMP Site 1 validated; annual revenue capacity $10M-$30M; new customer orders for LineaDNA.
Submitted H5N1 diagnostic validation to NYSDOH; investor call on June 3, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.